Information on EC 3.4.21.109 - matriptase

Word Map on EC 3.4.21.109
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY hide
3.4.21.109
-
RECOMMENDED NAME
GeneOntology No.
matriptase
-
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
cleaves various synthetic substrates with Arg or Lys at the P1 position and prefers small side-chain amino acids, such as Ala and Gly, at the P2 position
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
cleavage of C-N-linkage
hydrolysis of peptide bond
CAS REGISTRY NUMBER
COMMENTARY hide
241475-96-7
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
zebrafish
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
evolution
malfunction
metabolism
-
the matriptase zymogen is capable of intermolecular autoproteolytic activation, and the active enzyme is also an effective activator of the prostasin zymogen through direct proteolytic cleavage at its zymogen activation site. Prostasin is required for matriptase activation in intestinal epithelial cells to regulate closure of the paracellular pathway. Activated prostasin appears to target several downstream effector proteins, including the epithelial sodium channel and the G protein-coupled protease activated receptor-2, which are both matriptase substrates. Matriptase and not prostasin is the primary effector protease of tight junction assembly in simple columnar epithelia
physiological function
additional information
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(DY-681)-Gly-Arg-Gln-Ser-Arg-Ala-Ile-Lys (DY-681)-NH + H2O
?
show the reaction diagram
-
synthetic substrate, peptide sequence is derived from one of the preferred matriptase cleavage sequences, P4(Arg/Lys)-P3(Xxx)-P2(Ser)-P1(Arg)-P10(Ala), where Xxx is a nonbasic amino acid
-
-
?
ABZ-Ile-Arg-Ala-Arg-Ser-Ala-Ala-Tyr(3-NO2)-NH2 + H2O
ABZ-Ile-Arg-Ala-Arg + Ser-Ala-Ala-Tyr(3-NO2)-NH2
show the reaction diagram
-
-
-
-
?
ABZ-Ile-Arg-Ala-Arg-Ser-Ala-Gly-Tyr(3-NO2)-NH2 + H2O
ABZ-Ile-Arg-Ala-Arg + Ser-Ala-Gly-Tyr(3-NO2)-NH2
show the reaction diagram
-
-
-
-
?
ABZ-Ile-Arg-Ala-Arg-Ser-Ala-Ser-Tyr(3-NO2)-NH2 + H2O
ABZ-Ile-Arg-Ala-Arg + Ser-Ala-Ser-Tyr(3-NO2)-NH2
show the reaction diagram
-
-
-
-
?
acetyl-L-lysyl-L-threonyl-L-lysyl-L-glutaminyl-L-leucyl-L-arginine-4-methylcoumaryl-7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
acetyl-Lys-Thr-Lys-Gln-Leu-Arg-4-methyl-coumaryl-7-amide + H2O
acetyl-Lys-Thr-Lys-Gln-Leu-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
acetyl-Lys-Thr-Lys-Gln-Leu-Arg-4-methylcoumarin-7-amide + H2O
?
show the reaction diagram
-
substrate almost matches the P5 to P1 residues of matriptase zymogen: P5(Thr)-P4(Lys)-P3(Gln)-P2(Ala)-P1(Arg). The hydrolysis of the substrate is expected to mimic the situation of activation cleavage of matriptase zymogen
-
-
?
acetyl-Lys-Thr-Lys-Gln-Leu-Arg-methyl-coumaryl-7-amide + H2O
acetyl-Lys-Thr-Lys-Gln-Leu-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
relative activity: 19% using engineered L-matriptase (secreted variant of matriptase activated by recombinant enterokinase), relative activity: 16% using engineered pseudozymogen His6t-S-CD (consisting of a spacer and the catalytical domain with an N-terminal His6-tag and a cleavage site for activation by enterokinase)
-
-
?
acid-sensing ion channel 1 + H2O
?
show the reaction diagram
-
the matriptase recognition sites Arg-145, Lys-185, and Lys-384 are identified in the specific substrate acid-sensing ion channel 1
-
-
?
alphaEbeta7 + H2O
?
show the reaction diagram
-
-
-
-
?
alphaEbeta7integrin + H2O
?
show the reaction diagram
-
-
-
?
Arg-Xaa-Ser-Arg-Ala + H2O
Arg-Xaa-Ser + Arg-Ala
show the reaction diagram
-
X: non-basic amino acid, good substrate
-
?
benzoyl-L-arginine-4-methylcoumaryl-7-amide + H2O
benzoyl-L-arginine + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Gln-Ala-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Gln-Ala-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Val-Pro-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Val-Pro-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
Boc-Gln-Ala-Arg-4-nitroanilide + H2O
Boc-Gln-Ala-Arg + 4-nitroaniline
show the reaction diagram
-
-
-
?
Boc-Gln-Ala-Arg-7-amido-4-methylcoumarin + H2O
Boc-Gln-Ala-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
fluorogenic substrate
-
-
?
Boc-Glu-Ala-Arg-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
Boc-Glu-Ala-Arg-7-amido-4-methylcoumarin + H2O
Boc-Glu-Ala-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
Boc-QAR-Amc + H2O
?
show the reaction diagram
matriptase-2 mediates efficient cleavage of artificial peptides corresponding to cleavage sites located in the proteins filaggrin, CUB-domain-containing protein 1 (CDCP1), and alphaE beta7 integrin
-
-
?
Bovine serum albumin + H2O
?
show the reaction diagram
-
-
-
-
?
butyloxycarbonyl-L-Gln-L-Ala-L-Arg-4-nitroanilide + H2O
butyloxycarbonyl-L-Gln-L-Ala-L-Arg + 4-nitroaniline
show the reaction diagram
-
-
-
-
?
casein + H2O
?
show the reaction diagram
-
-
-
-
?
CDCP1 + H2O
?
show the reaction diagram
collagen type IV + H2O
?
show the reaction diagram
CUB-domain-containing protein 1 + H2O
?
show the reaction diagram
-
-
-
?
denatured collagen + H2O
?
show the reaction diagram
-
-
-
-
?
epidermal growth factor receptor + H2O
EGFR135 + EGFR110
show the reaction diagram
fetuin-A + H2O
?
show the reaction diagram
-
a liver-derived alpha2-Heremans-Schmid glycoprotein from plasma, processing into a two-chain form, cleavage sites are Arg and Lys residues in the 40 amino acid sequence of the linker connceting the two peptides
-
-
?
Fibrinogen + H2O
?
show the reaction diagram
-
-
-
?
Fibronectin + H2O
?
show the reaction diagram
filaggrin + H2O
?
show the reaction diagram
G-protein-coupled protease-activated receptor-2 + H2O
?
show the reaction diagram
Gelatin + H2O
?
show the reaction diagram
Glu-Gly-Arg-p-nitroanilide + H2O
?
show the reaction diagram
-
substrate activity assay
-
-
?
growth factor macrophage-stimulating protein 1 + H2O
?
show the reaction diagram
H-Glu-Gly-Arg-p-nitroanilide + H2O
H-Glu-Gly + Arg-p-nitroanilide
show the reaction diagram
-
low activity
-
-
?
hemojuvelin (furin site) + H2O
?
show the reaction diagram
-
-
-
?
hemojuvelin + H2O
?
show the reaction diagram
hepatocyte growth factor + H2O
?
show the reaction diagram
-
-
-
?
hepatocyte growth factor + H2O
activated hepatocyte growth factor + ?
show the reaction diagram
hepatocyte growth factor/scatter factor + H2O
activated hepatocyte growth factor/scatter factor + ?
show the reaction diagram
HGF/SF + H2O
?
show the reaction diagram
-
i.e. hepatocyte growth factor/scatter factor, growth factor
-
-
?
IGFBP-rP1 + H2O
?
show the reaction diagram
influenza A H1 virus hemagglutinin + H2O
?
show the reaction diagram
-
the soluble form of the protease is able to specifically cleave hemagglutinins from H1 virus, but not from H2 and H3 viruses, in a broad pH range
-
-
?
insulin growth factor binding protein-related protein-1 + H2O
?
show the reaction diagram
-
cleaved by the soluble form of active matripase
-
-
?
insulin-like growth factor binding protein related protein-1
?
show the reaction diagram
-
IGFBP-rP1
-
-
?
insulin-like growth factor binding protein-related protein-1 + H2O
?
show the reaction diagram
insulin-like growth factor binding-related protein-1 + H2O
?
show the reaction diagram
Laminin + H2O
?
show the reaction diagram
Lys-Xaa-Ser-Arg-Ala + H2O
Lys-Xaa-Ser + Arg-Ala
show the reaction diagram
-
X: non-basic amino acid, good substrate
-
?
matriptase + H2O
?
show the reaction diagram
-
-
-
-
?
matriptase-2 + H2O
?
show the reaction diagram
-
autocatalysis
-
-
?
matrix metalloprotease-3 + H2O
?
show the reaction diagram
methyl-sulfonyl-D-cyclo-hexyltyrosyl-glycyl-L-arginine-4-nitroanilide + H2O
?
show the reaction diagram
-
-
-
?
methylsulfonyl-D-cyclohexyltyrosyl-glycyl-arginine-p-nitroanilide + H2O
methylsulfonyl-D-cyclohexyltyrosyl-glycyl-arginine + p-nitroaniline
show the reaction diagram
-
-
-
-
?
methylsulfonyl-D-cyclohexyltyrosylglycyl-arginine-p-nitroanilide + H2O
methylsulfonyl-D-cyclohexyltyrosylglycyl-arginine + p-nitroaniline
show the reaction diagram
-
-
-
-
?
MSP-1 + H2O
?
show the reaction diagram
-
i.e. macrophage-stimulating protein 1, a growth factor
-
-
?
N-Ala-Ala-Ala-Tyr-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
N-succinyl-Ala-Phe-Lys-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
N-succinyl-Ala-Phe-Lys-7-amido-4-methylcoumarin + H2O
N-succinyl-Ala-Phe-Lys + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
N-succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
N-tert-butoxy-carbonyl-Gln-Ala-Arg-7-amido-4-methylcoumarin
N-tert-butoxy-carbonyl-Gln-Ala-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
?
N-tert-butoxycarbonyl-benzyl-Asp-Pro-Arg-7-amido-4-methylcoumarin + H2O
N-tert-butoxycarbonyl-benzyl-Asp-Pro-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
N-tert-butoxycarbonyl-benzyl-Glu-Gly-Arg-7-amido-4-methylcoumarin + H2O
N-tert-butoxycarbonyl-benzyl-Glu-Gly-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
N-tert-butoxycarbonyl-gamma-benzyl-Gln-Ala-Arg-7-amido-4-methylcoumarin + H2O
N-tert-butoxycarbonyl-gamma-benzyl-Gln-Ala-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
N-tert-butoxycarbonyl-gamma-benzyl-Glu-Ala-Arg-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
N-tert-butoxycarbonyl-gamma-benzyl-Glu-Ala-Arg-7-amido-4-methylcoumarin + H2O
N-tert-butoxycarbonyl-gamma-benzyl-Glu-Ala-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
N-tert-butoxycarbonyl-gamma-benzyl-Glu-Gly-Arg-7-amido-4-methylcoumarin + H2O
N-tert-butoxycarbonyl-gamma-benzyl-Glu-Gly-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
N-tert-butoxycarbonyl-gamma-benzyl-Leu-Gly-Arg-7-amido-4-methylcoumarin + H2O
N-tert-butoxycarbonyl-gamma-benzyl-Leu-Gly-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
N-tert-butoxycarbonyl-Gln-Ala-Arg-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
N-tert-butoxycarbonyl-Gln-Ala-Arg-7-amido-4-methylcoumarin + H2O
N-tert-butoxycarbonyl-Gln-Ala-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
N-tert-butoxycarbonyl-Gly-Lys-Arg-7-amido-4-methylcoumarin + H2O
N-tert-butoxycarbonyl-Gly-Lys-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
N-tert-butoxycarbonyl-Leu-Arg-Arg-7-amido-4-methylcoumarin + H2O
N-tert-butoxycarbonyl-Leu-Arg-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
N-tert-butoxycarbonyl-Leu-Gly-Arg-7-amido-4-methylcoumarin + H2O
N-tert-butoxycarbonyl-Leu-Gly-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
N-tert-butoxycarbonyl-Leu-Ser-Thr-Arg-7-amido-4-methylcoumarin + H2O
N-tert-butoxycarbonyl-Leu-Ser-Thr-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
N-tert-butoxycarbonyl-Phe-Ser-Arg-7-amido-4-methylcoumarin + H2O
N-tert-butoxycarbonyl-Phe-Ser-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
N-tert-butoxycarbonyl-Val-Pro-Arg-7-amido-4-methylcoumarin + H2O
N-tert-butoxycarbonyl-Val-Pro-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
N2-t-butyloxycarbonyl-QNR-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
matriptase-2 mediates efficient cleavage of artificial peptides corresponding to cleavage sites located in the proteins filaggrin, CUB-domain-containing protein 1 (CDCP1), and alphaE beta7 integrin
-
-
?
PAR-2 + H2O
?
show the reaction diagram
plasminogen + H2O
?
show the reaction diagram
-
-
-
?
pro matrix metalloproteinase 1 + H2O
?
show the reaction diagram
-
matriptase activates pro-matrix metalloproteinase-1 and processes pro-matrix metalloproteinase-3 to its fully active form
-
-
?
pro matrix metalloproteinase 3 + H2O
?
show the reaction diagram
-
matriptase activates pro-matrix metalloproteinase-1 and processes pro-matrix metalloproteinase-3 to its fully active form
-
-
?
pro-form GPI-anchored serine protease prostasin + H2O
mature GPI-anchored serine protease prostasin + ?
show the reaction diagram
pro-form influenza hemagglutinin H1 + H2O
mature influenza hemagglutinin H1 + ?
show the reaction diagram
pro-form influenza hemagglutinin H2 + H2O
mature influenza hemagglutinin H2 + ?
show the reaction diagram
-
subtype H2N2
-
-
?
pro-form influenza hemagglutinin H3 + H2O
mature influenza hemagglutinin H3 + ?
show the reaction diagram
-
subtype H3N2
-
-
?
pro-form matriptase + H2O
mature matriptase + ?
show the reaction diagram
-
autocatalytic activation
-
-
?
pro-hepatocyte growth factor + H2O
?
show the reaction diagram
pro-hepatocyte growth factor/scatter factor + H2O
?
show the reaction diagram
-
pro-HGF/SF
-
-
?
pro-HGF + H2O
?
show the reaction diagram
-
matriptase is an efficient activator of hepatocyte growth factor
-
-
?
pro-prostasin + H2O
prostasin + propeptide of prostasin
show the reaction diagram
pro-uPA + H2O
?
show the reaction diagram
-
-
-
-
?
pro-urokinase plasminogen activator + H2O
?
show the reaction diagram
-
-
-
?
pro-urokinase plasminogen activator + H2O
urokinase plasminogen activator + propeptide of urokinase plasminogen activator
show the reaction diagram
pro-urokinase-type plasminogen activator + H2O
?
show the reaction diagram
profilaggrin + H2O
?
show the reaction diagram
-
-
-
-
?
profilaggrin + H2O
filaggrin + propeptide of filaggrin
show the reaction diagram
proform acid-sensing ion channel 1 + H2O
mature acid-sensing ion channel 1 + ?
show the reaction diagram
-
-
-
-
?
proform epithelial sodium channel + H2O
mature epithelial sodium channel + ?
show the reaction diagram
-
-
-
-
?
proform G protein-coupled protease activated receptor-2 + H2O
mature G protein-coupled protease activated receptor-2 + ?
show the reaction diagram
-
-
-
-
?
proform G-protein-coupled protease activated receptor-2 + H2O
mature G-protein-coupled protease activated receptor-2 + ?
show the reaction diagram
-
-
-
-
?
proform hepatocyte growth factor + H2O
mature hepatocyte growth factor + ?
show the reaction diagram
-
-
-
-
?
proform matriptase + H2O
mature matriptase
show the reaction diagram
-
matriptase is expressed as a zymogen and is autocatalytically processed and activated through cleavage at Arg614 within the RQAR614-VVGG activation sequence
-
-
?
proform matriptase-2 + H2O
mature matriptase
show the reaction diagram
-
matriptase-2 is expressed as zymogen form and undergoes autocatalysis at Arg576 within the PSSR576-IVGG sequence located in the consensus activation site of its pro-domain
-
-
?
proform platelet-derived growth factor-D + H2O
mature platelet-derived growth factor-D + ?
show the reaction diagram
-
-
-
-
?
proform prostasin + H2O
mature prostasin + ?
show the reaction diagram
proform urokinase-type plasminogen activator + H2O
mature urokinase-type plasminogen activator + ?
show the reaction diagram
-
-
-
-
?
prostasin + H2O
?
show the reaction diagram
prostasin + H2O
activated prostasin + ?
show the reaction diagram
prostatin + H2O
?
show the reaction diagram
protease activated receptor 2 + H2O
?
show the reaction diagram
-
-
-
-
?
protease-activated receptor-2
?
show the reaction diagram
-
PAR2
-
-
?
protease-activated receptor-2 + H2O
?
show the reaction diagram
-
-
-
-
?
proteinase-activated receptor 2 + H2O
?
show the reaction diagram
-
-
-
-
?
RAARVVGG + H2O
RAAR + VVGG
show the reaction diagram
-
-
-
-
?
RLARVVGG + H2O
RLAR + VVGG
show the reaction diagram
-
-
-
-
?
RQARAVGG + H2O
RQAR + AVGG
show the reaction diagram
-
-
-
-
?
RQARQVGG + H2O
RQAR + QVGG
show the reaction diagram
-
-
-
-
?
RQARVVGG + H2O
RQAR + VVGG
show the reaction diagram
-
-
-
-
?
RQARYVGG + H2O
RQAR + YVGG
show the reaction diagram
-
-
-
-
?
RQLRVVGG + H2O
RQLR + VVGG
show the reaction diagram
-
-
-
-
?
RQRRVVGG + H2O
RQRR + VVGG
show the reaction diagram
-
-
-
-
?
RQYRVVGG + H2O
RQYR + VVGG
show the reaction diagram
-
-
-
-
?
RRARVVGG + H2O
RRAR + VVGG
show the reaction diagram
-
-
-
-
?
RYARVVGG + H2O
RYAR + VVGG
show the reaction diagram
-
-
-
-
?
serine protease uPA + H2O
?
show the reaction diagram
SIMA135 + H2O
?
show the reaction diagram
single-chain urokinase-type plaminogen activator + H2O
?
show the reaction diagram
-
is activated by matriptase
-
?
single-chain urokinase-type plasminogen activator + H2O
?
show the reaction diagram
-
sc-uPA
-
-
?
stromelysin + H2O
?
show the reaction diagram
-
MMP-3
-
-
?
stromelysin + H2O
activated stromelysin + propeptide of stromelysin
show the reaction diagram
Suc-Ala-Ala-Pro-Arg-p-nitroanilide + H2O
Suc-Ala-Ala-Pro + Arg-p-nitroanilide
show the reaction diagram
-
low activity
-
-
?
Suc-Ala-Ala-Pro-Lys-p-nitroanilide + H2O
Suc-Ala-Ala-Pro-Lys + p-nitroaniline
show the reaction diagram
-
-
-
-
?
succinyl-Ala-Phe-Lys-7-amido-4-methylcoumarin + H2O
succinyl-Ala-Phe-Lys + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
t-butoxycarbonyl-L-Gln-L-Ala-L-Arg-7-amido-4-methylcoumarin + H2O
t-butoxycarbonyl-L-Gln-L-Ala-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
t-butyloxycarbonyl-Asp-Pro-Arg-methyl-coumaryl-7-amide + H2O
t-butyloxycarbonyl-Asp-Pro-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
relative activity: 66% using engineered L-matriptase (secreted variant of matriptase activated by recombinant enterokinase), relative activity: 69% using engineered pseudozymogen His6t-S-CD (consisting of a spacer and the catalytical domain with an N-terminal His6-tag and a cleavage site for activation by enterokinase)
-
-
?
t-butyloxycarbonyl-Gln-Ala-Arg-4-methyl-coumaryl-7-amide + H2O
t-butyloxycarbonyl-Gln-Ala-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
t-butyloxycarbonyl-Gln-Ala-Arg-7-amido-4-methylcoumarin + H2O
t-butyloxycarbonyl-Gln-Ala-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
enzymatic activity assay
-
-
?
t-butyloxycarbonyl-Gln-Ala-Arg-methyl-coumaryl-7-amide + H2O
t-butyloxycarbonyl-Gln-Ala-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
relative activity: 100%, using engineered L-matriptase (secreted variant of matriptase activated by recombinant enterokinase) or engineered pseudozymogen His6t-S-CD (consisting of a spacer and the catalytical domain with an N-terminal His6-tag and a cleavage site for activation by enterokinase)
-
-
?
t-butyloxycarbonyl-Glu-Gly-Arg-methyl-coumaryl-7-amide + H2O
t-butyloxycarbonyl-Glu-Gly-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
relative activity: 29% using engineered L-matriptase (secreted variant of matriptase activated by recombinant enterokinase), relative activity: 31% using engineered pseudozymogen His6t-S-CD (consisting of a spacer and the catalytical domain with an N-terminal His6-tag and a cleavage site for activation by enterokinase)
-
-
?
t-butyloxycarbonyl-L-Gln-L-Ala-L-Arg-4-methyl-coumaryl-7-amide + H2O
t-butyloxycarbonyl-L-Gln-L-Ala-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
activity assay
-
-
?
t-butyloxycarbonyl-L-glutamyl-L-alanyl-L-arginine-4-methylcoumaryl-7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
t-butyloxycarbonyl-Leu-Gly-Arg-methyl-coumaryl-7-amide + H2O
t-butyloxycarbonyl-Leu-Gly-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
relative activity: 28% using engineered L-matriptase (secreted variant of matriptase activated by recombinant enterokinase), relative activity: 28% using engineered pseudozymogen His6t-S-CD (consisting of a spacer and the catalytical domain with an N-terminal His6-tag and a cleavage site for activation by enterokinase)
-
-
?
t-butyloxycarbonyl-Phe-Ser-Arg-methyl-coumaryl-7-amide + H2O
t-butyloxycarbonyl-Phe-Ser-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
relative activity: 12% using engineered L-matriptase (secreted variant of matriptase activated by recombinant enterokinase), relative activity: 13% using engineered pseudozymogen His6t-S-CD (consisting of a spacer and the catalytical domain with an N-terminal His6-tag and a cleavage site for activation by enterokinase)
-
-
?
t-butyloxycarbonyl-[(2S)-2-amino-3-(benzyloxycarbonyl)propionyl]-L-prolyl-L-arginine-4-methylcoumaryl-7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
t-butyloxycarbonyl-[(2S)-2-amino-3-(benzyloxycarbonyl)propionyl]-Pro-Arg-4-methyl-coumaryl-7-amide + H2O
t-butyloxycarbonyl-[(2S)-2-amino-3-(benzyloxycarbonyl)propionyl]-Pro-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
TMPRSS6 + H2O
?
show the reaction diagram
autocleavage site: PSSR/IVGG
-
-
?
trask + H2O
?
show the reaction diagram
Type I collagen + H2O
?
show the reaction diagram
-
-
-
?
urokinase plasminogen activator + H2O
urokinase plasminogen activator + propeptide of urokinase plasminogen activator
show the reaction diagram
VEGFR-2 + H2O
?
show the reaction diagram
VPEKQTRGL + H2O
?
show the reaction diagram
-
influenza hemagglutinin H3 cleavage site peptide mimic
-
-
?
Xaa-Arg-Ser-Arg-Ala + H2O
Xaa-Arg-Ser + Arg-Ala
show the reaction diagram
-
X: non-basic amino acid, good substrate
-
?
Xaa-Lys-Ser-Arg-Ala + H2O
Xaa-Lys-Ser + Arg-Ala
show the reaction diagram
-
X: non-basic amino acid, good substrate
-
?
Z-Phe-Val-Arg-p-nitroanilide + H2O
Z-Phe-Val + Arg-p-nitroanilide
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
acid-sensing ion channel 1 + H2O
?
show the reaction diagram
-
the matriptase recognition sites Arg-145, Lys-185, and Lys-384 are identified in the specific substrate acid-sensing ion channel 1
-
-
?
butyloxycarbonyl-L-Gln-L-Ala-L-Arg-4-nitroanilide + H2O
butyloxycarbonyl-L-Gln-L-Ala-L-Arg + 4-nitroaniline
show the reaction diagram
-
-
-
-
?
CDCP1 + H2O
?
show the reaction diagram
collagen type IV + H2O
?
show the reaction diagram
epidermal growth factor receptor + H2O
EGFR135 + EGFR110
show the reaction diagram
-
the epidermal growth factor receptor, EGFR is proteolytically cleaved in the N-terminal extracellular domain by the matriptase-prostasin serine protease cascade in cultured epithelial cells
fragments of 135 and 110 kDa, no longer responsive to EGF stimulation
-
?
Fibronectin + H2O
?
show the reaction diagram
G-protein-coupled protease-activated receptor-2 + H2O
?
show the reaction diagram
Gelatin + H2O
?
show the reaction diagram
growth factor macrophage-stimulating protein 1 + H2O
?
show the reaction diagram
hemojuvelin + H2O
?
show the reaction diagram
hepatocyte growth factor + H2O
activated hepatocyte growth factor + ?
show the reaction diagram
hepatocyte growth factor/scatter factor + H2O
activated hepatocyte growth factor/scatter factor + ?
show the reaction diagram
HGF/SF + H2O
?
show the reaction diagram
-
i.e. hepatocyte growth factor/scatter factor, growth factor
-
-
?
IGFBP-rP1 + H2O
?
show the reaction diagram
influenza A H1 virus hemagglutinin + H2O
?
show the reaction diagram
-
the soluble form of the protease is able to specifically cleave hemagglutinins from H1 virus, but not from H2 and H3 viruses, in a broad pH range
-
-
?
insulin-like growth factor binding protein related protein-1
?
show the reaction diagram
-
IGFBP-rP1
-
-
?
insulin-like growth factor binding protein-related protein-1 + H2O
?
show the reaction diagram
insulin-like growth factor binding-related protein-1 + H2O
?
show the reaction diagram
Laminin + H2O
?
show the reaction diagram
matriptase-2 + H2O
?
show the reaction diagram
-
autocatalysis
-
-
?
matrix metalloprotease-3 + H2O
?
show the reaction diagram
-
activation
-
-
?
MSP-1 + H2O
?
show the reaction diagram
-
i.e. macrophage-stimulating protein 1, a growth factor
-
-
?
PAR-2 + H2O
?
show the reaction diagram
pro matrix metalloproteinase 1 + H2O
?
show the reaction diagram
-
matriptase activates pro-matrix metalloproteinase-1 and processes pro-matrix metalloproteinase-3 to its fully active form
-
-
?
pro matrix metalloproteinase 3 + H2O
?
show the reaction diagram
-
matriptase activates pro-matrix metalloproteinase-1 and processes pro-matrix metalloproteinase-3 to its fully active form
-
-
?
pro-form GPI-anchored serine protease prostasin + H2O
mature GPI-anchored serine protease prostasin + ?
show the reaction diagram
-
activation, prostasin is also a regulator of the epidermal sodium channel like matriptase
-
-
?
pro-form influenza hemagglutinin H1 + H2O
mature influenza hemagglutinin H1 + ?
show the reaction diagram
-
-
-
-
?
pro-form matriptase + H2O
mature matriptase + ?
show the reaction diagram
-
autocatalytic activation
-
-
?
pro-hepatocyte growth factor + H2O
?
show the reaction diagram
pro-hepatocyte growth factor/scatter factor + H2O
?
show the reaction diagram
-
pro-HGF/SF
-
-
?
pro-HGF + H2O
?
show the reaction diagram
-
matriptase is an efficient activator of hepatocyte growth factor
-
-
?
pro-prostasin + H2O
prostasin + propeptide of prostasin
show the reaction diagram
pro-uPA + H2O
?
show the reaction diagram
-
-
-
-
?
pro-urokinase plasminogen activator + H2O
urokinase plasminogen activator + propeptide of urokinase plasminogen activator
show the reaction diagram
pro-urokinase-type plasminogen activator + H2O
?
show the reaction diagram
profilaggrin + H2O
?
show the reaction diagram
-
-
-
-
?
profilaggrin + H2O
filaggrin + propeptide of filaggrin
show the reaction diagram
proform epithelial sodium channel + H2O
mature epithelial sodium channel + ?
show the reaction diagram
-
-
-
-
?
proform G protein-coupled protease activated receptor-2 + H2O
mature G protein-coupled protease activated receptor-2 + ?
show the reaction diagram
-
-
-
-
?
proform hepatocyte growth factor + H2O
mature hepatocyte growth factor + ?
show the reaction diagram
-
-
-
-
?
proform matriptase + H2O
mature matriptase
show the reaction diagram
-
matriptase is expressed as a zymogen and is autocatalytically processed and activated through cleavage at Arg614 within the RQAR614-VVGG activation sequence
-
-
?
proform matriptase-2 + H2O
mature matriptase
show the reaction diagram
-
matriptase-2 is expressed as zymogen form and undergoes autocatalysis at Arg576 within the PSSR576-IVGG sequence located in the consensus activation site of its pro-domain
-
-
?
proform prostasin + H2O
mature prostasin + ?
show the reaction diagram
prostasin + H2O
?
show the reaction diagram
prostasin + H2O
activated prostasin + ?
show the reaction diagram
-
proteolytic activation by matriptase, when expressed without matriptase, prostasin remains in the zymogen form and no prostasin-PN-1 complex is formed, overview
-
-
?
prostatin + H2O
?
show the reaction diagram
protease activated receptor 2 + H2O
?
show the reaction diagram
-
-
-
-
?
protease-activated receptor-2
?
show the reaction diagram
-
PAR2
-
-
?
proteinase-activated receptor 2 + H2O
?
show the reaction diagram
-
-
-
-
?
serine protease uPA + H2O
?
show the reaction diagram
SIMA135 + H2O
?
show the reaction diagram
single-chain urokinase-type plasminogen activator + H2O
?
show the reaction diagram
-
sc-uPA
-
-
?
stromelysin + H2O
?
show the reaction diagram
-
MMP-3
-
-
?
stromelysin + H2O
activated stromelysin + propeptide of stromelysin
show the reaction diagram
-
activation
-
-
?
trask + H2O
?
show the reaction diagram
urokinase plasminogen activator + H2O
urokinase plasminogen activator + propeptide of urokinase plasminogen activator
show the reaction diagram
VEGFR-2 + H2O
?
show the reaction diagram
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Na+
-
in a buffer containing 5 mM NaCl the activity of a pseudozymogen form of recombinant matriptase (HL-matriptase) is only 30times lower than that of the respective two-chain form (activated form after enterokinase treatment)
additional information
-
low intracellular iron increases the stability of matriptase-2, overview
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1r,4r)-4-amino-N-(3,5-bis(4-carbamimidoylphenoxy)phenyl)cyclohexanecarboxamide
-
-
(1r,4r)-4-aminocyclohexyl 3,5-bis(4-carbamimidoylphenoxy)benzoate
-
-
(2R)-1-(N-[[3-(beta-alanylamino)phenyl]sulfonyl]-3-carbamimidoyl-L-phenylalanyl)piperidine-2-carboxylic acid
-
-
(2S)-1-(N-[[3-(beta-alanylamino)phenyl]sulfonyl]-3-carbamimidoyl-L-phenylalanyl)piperidine-2-carboxylic acid
-
-
1-(2-aminoethyl)-N-(3,5-bis(4-carbamimidoylphenoxy)phenyl)piperidine-4-carboxamide
-
-
1-(3,5-bis(4-carbamimidoylphenoxy)benzoyl)piperidine-4-carboxylic acid
-
-
1-(3-aminopropanoyl)-N-(3,5-bis(4-carbamimidoylphenoxy)phenyl)piperidine-4-carboxamide
-
-
1-(N-[[3-(b-alanylamino)phenyl]sulfonyl]-3-carbamimidoyl-L-phenylalanyl)piperidine-3-carboxamide
-
-
1-(N-[[3-(beta-alanylamino)phenyl]sulfonyl]-3-carbamimidoyl-L-phenylalanyl)piperidine-4-carboxamide
-
-
1-[(4S)-4-amino-5-(1,3-benzothiazol-2-yl)-5-oxopentyl]guanidine
-
2-(L-alanyl-L-arginyl)-1,3-benzothiazole
-
2-Nas-Phe(3-Am)-4-(2-guanidinoethyl)piperidide
-
-
3,5-bis(4-carbamimidoylphenoxy)-N-((4-hydroxycyclohexyl)methyl)benzamide
-
-
3,5-bis(4-carbamimidoylphenoxy)-N-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide
-
-
3,5-bis(4-carbamimidoylphenoxy)-N-(4-fluorophenyl)benzamide
-
-
3,5-bis(4-carbamimidoylphenoxy)-N-(4-hydroxycyclohexyl)benzamide
-
-
3,5-bis(4-carbamimidoylphenoxy)-N-(4-methylcyclohexyl)benzamide
-
-
3,5-bis(4-carbamimidoylphenoxy)-N-(cyclohexylmethyl)benzamide
-
-
3,5-bis(4-carbamimidoylphenoxy)-N-cyclohexylbenzamide
-
-
3,5-bis(4-carbamimidoylphenoxy)benzamide
-
-
3-(3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[(4'-ethylbiphenyl-3-yl)sulfonyl]amino]-3-oxopropyl)benzenecarboximidamide
-
inhibitor completely prevents matriptase zymogen activation in human adenocarcinoma cell lines AsPC-1 and BxPC-3. Pro-urokinase-type plasminogen activator activation is completely abolished by matriptase inhibition. Matriptase inhibitors reduce the phosphorylation of the HGF receptor/cMet and the overall cellular invasiveness of the human pancreatic adenocarcinoma cell line AsPC-1
3-TAPAP
-
-
3-[(2R)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-([[3-(6-amino-2,3,4,5-tetrahydropyridin-3-yl)phenyl]sulfonyl]amino)-3-oxopropyl]benzenecarboximidamide
-
-
3-[(2R)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-[(naphthalen-2-ylsulfonyl)amino]propyl]benzenecarboximidamide
-
-
3-[(2S)-2-([[3-(4-aminobutyl)phenyl]sulfonyl]amino)-3-[4-(2-aminoethyl)piperidin-1-yl]-3-oxopropyl]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-([[3-(1H-indol-5-yl)phenyl]sulfonyl]amino)-3-oxopropyl]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-([[3-(2-methylpyrimidin-4-yl)phenyl]sulfonyl]amino)-3-oxopropyl]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-([[3-(6-amino-2,3,4,5-tetrahydropyridin-3-yl)phenyl]sulfonyl]amino)-3-oxopropyl]benzenecarboximidamide
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-([[3-(6-aminopyridin-3-yl)phenyl]sulfonyl]amino)-3-oxopropyl]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-([[4'-(1-methylethoxy)biphenyl-3-yl]sulfonyl]amino)-3-oxopropyl]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[(biphenyl-3-ylsulfonyl)amino]-3-oxopropyl]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[(naphthalen-2-ylsulfonyl)amino]-3-oxopropoxy]benzenecarboximidamide
-
higher cytotoxic effect, enzyme-bound structure, crystal structure analysis, overview
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[([3-[(3-aminopropyl)amino]phenyl]sulfonyl)amino]-3-oxopropyl]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[(2'-chlorobiphenyl-3-yl)sulfonyl]amino]-3-oxopropyl]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[(3',4'-dimethoxybiphenyl-3-yl)sulfonyl]amino]-3-oxopropyl]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[(3'-chlorobiphenyl-3-yl)sulfonyl]amino]-3-oxopropyl]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[(4'-chlorobiphenyl-3-yl)sulfonyl]amino]-3-oxopropyl]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[(4'-ethoxybiphenyl-3-yl)sulfonyl]amino]-3-oxopropyl]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[(4'-ethylbiphenyl-3-yl)sulfonyl]amino]-3-oxopropyl]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[(4'-methoxybiphenyl-3-yl)sulfonyl]amino]-3-oxopropyl]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[(4-cyclohexylphenyl)sulfonyl]amino]-3-oxopropoxy]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-3-oxo-2-([[2,4,6-tri(propan-2-yl)phenyl]sulfonyl]amino)propoxy]benzenecarboximidamide
-
higher cytotoxic effect
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-3-oxo-2-[[(3-pyridin-3-ylphenyl)sulfonyl]amino]propyl]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-3-oxo-2-[[(3-pyridin-4-ylphenyl)sulfonyl]amino]propyl]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(4-aminobutanoyl)piperidin-1-yl]-3-oxo-2-([[2,4,6-tri(propan-2-yl)phenyl]sulfonyl]amino)propoxy]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(b-alanyl)piperidin-1-yl]-3-oxo-2-([[2,4,6-tri(propan-2-yl)phenyl]sulfonyl]amino)propoxy]benzenecarboximidamide
-
-
3-[(2S)-3-[4-(N-carbamimidoyl-b-alanyl)piperazin-1-yl]-3-oxo-2-([[2,4,6-tris(1-methylethyl)phenyl]sulfonyl]amino)propyl]benzenecarboximidamide
-
-
3-[3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-[(naphthalen-2-ylsulfonyl)amino]-3-oxopropyl]benzenecarboximidamide
-
-
4,4'-((5-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1,3-phenylene)bis(oxy))dibenzimidamide
-
-
4,4'-((5-(4-(2-aminoethyl)piperidine-1-carbonyl)-1,3-phenylene)bis(oxy))dibenzimidamide
-
-
4,4'-((5-(4-fluorophenylsulfonamido)-1,3-phenylene)bis(oxy))dibenzimidamide
-
-
4,4'-((5-(decahydroquinoline-1-carbonyl)-1,3-phenylene)bis(oxy))dibenzimidamide
-
-
4,4'-((5-(naphthalene-2-sulfonamido)-1,3-phenylene)bis(oxy))dibenzimidamide
-
-
4,4'-[(3-[[(4-fluorophenyl)sulfonyl]amino]pyridine-2,6-diyl)bis(oxy)]dibenzenecarboximidamide
-
-
4,4'-[(5-aminobenzene-1,3-diyl)bis(oxy)]dibenzenecarboximidamide
-
-
4,4'-[benzene-1,4-diylbis(oxy)]dibenzenecarboximidamide
-
binding structure, overview
4-(1-[3-carbamimidoyl-N-[(3-pyrrolidin-1-ylphenyl)sulfonyl]-L-phenylalanyl]piperidin-4-yl)-N-methylbutanamide
-
-
4-(1-[3-carbamimidoyl-N-[(4'-ethoxybiphenyl-3-yl)sulfonyl]-L-phenylalanyl]piperidin-4-yl)-N-methylbutanamide
-
-
4-(1-[3-carbamimidoyl-N-[(4'-ethylbiphenyl-3-yl)sulfonyl]-L-phenylalanyl]piperidin-4-yl)-N-methylbutanamide
4-(1-[N-[(4'-tert-butylbiphenyl-3-yl)sulfonyl]-3-carbamimidoyl-L-phenylalanyl]piperidin-4-yl)-N-methylbutanamide
-
-
4-(2-aminoethyl)-benzenesulfonylfluoride hydrochloride
-
AEBSF
4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride
-
; inhibition of IGFBP-rP1 processing
4-([1-[(2S)-3-(3-carbamimidoylphenyl)-2-([[2,4,6-tris(1-methylethyl)phenyl]sulfonyl]amino)propanoyl]piperidin-4-yl]carbonyl)piperidine-1-carboximidamide
-
-
4-([1-[(2S)-3-(3-carbamimidoylphenyl)-2-[[(4-cyclohexylphenyl)sulfonyl]amino]propanoyl]piperidin-4-yl]carbonyl)piperidine-1-carboximidamide
-
inhibitor completely prevents matriptase zymogen activation in human adenocarcinoma cell lines AsPC-1 and BxPC-3. Pro-urokinase-type plasminogen activator activation is completely abolished by matriptase inhibition. Matriptase inhibitor reduce the phosphorylation of the HGF receptor/cMet and the overall cellular invasiveness of the human pancreatic adenocarcinoma cell line AsPC-1
4-aminobenzamidine
-
weak competitive inhibition, competition assay with antibody inhibitors, overview
4-aminocyclohexyl 3,5-bis(4-carbamimidoylphenoxy)benzoate
-
-
4-[(2-[[(2S)-6-carbamimidamido-1-oxohexan-2-yl]amino]-2-oxoethyl)carbamoyl]-6-methoxy-6-oxo-4-[3-(prop-1-en-2-yl)benzyl]hexanoic acid
-
-
4-[1-(3-carbamimidoyl-N-[[3-(1H-imidazol-1-yl)phenyl]sulfonyl]-L-phenylalanyl)piperidin-4-yl]-N-methylbutanamide
-
-
4-[1-(3-carbamimidoyl-N-[[3-(2-oxopiperazin-1-yl)phenyl]sulfonyl]-L-phenylalanyl)piperidin-4-yl]-N-methylbutanamide
-
-
4-[1-(3-carbamimidoyl-N-[[3-(2-oxopiperidin-1-yl)phenyl]sulfonyl]-L-phenylalanyl)piperidin-4-yl]-N-methylbutanamide
-
-
4-[1-(3-carbamimidoyl-N-[[3-(6-oxopyridazin-1(6H)-yl)phenyl]sulfonyl]-L-phenylalanyl)piperidin-4-yl]-N-methylbutanamide
-
-
4-[1-(N-[[3-(6-amino-2,3,4,5-tetrahydropyridin-3-yl)phenyl]sulfonyl]-3-carbamimidoyl-L-phenylalanyl)piperidin-4-yl]-N-methylbutanamide
-
-
4-[1-(N-[[3-(6-aminopyridin-3-yl)phenyl]sulfonyl]-3-carbamimidoyl-L-phenylalanyl)piperidin-4-yl]-N-methylbutanamide
-
-
4-[1-(N-[[3-(beta-alanylamino)phenyl]sulfonyl]-3-carbamimidoyl-L-phenylalanyl)piperidin-4-yl]-N-methylbutanamide
-
-
4-[1-(N-[[3-(beta-alanylamino)phenyl]sulfonyl]-3-carbamimidoyl-L-phenylalanyl)piperidin-4-yl]butanamide
-
-
4-[1-(N-[[3-(beta-alanylamino)phenyl]sulfonyl]-3-carbamimidoyl-L-phenylalanyl)piperidin-4-yl]butanoic acid
-
-
4-[4-(N-[[3-(beta-alanylamino)phenyl]sulfonyl]-3-carbamimidoyl-L-phenylalanyl)piperazin-1-yl]-N-methyl-4-oxobutanamide
-
-
alpha-1-antitrypsin
-
alpha-2-Antiplasmin
-
alpha1 proteinase
-
formation of a stable inhibitor complex
-
Alpha1-antitrypsin
-
AAT
-
alpha2-antiplasmin
-
anti-matriptase LDL receptor domain 3-specific monoclonal antibodies
-
complete inhibition of enzyme activation
-
antisense-matripase
-
significantly reduces matripase protein expression by 70-80%, anti-tumoral activity on HRA cells intraperitoneal injected into nude mice
-
antithrombin III
-
Aprotinin
ARCTKSIPPICFPD
-
a mutant of sunflower trypsin inhibitor-18
-
benzyl 4-(N-[[3-(beta-alanylamino)phenyl]sulfonyl]-3-carbamimidoyl-L-phenylalanyl)piperazine-1-carboxylate
benzylsulfonyl-D-arginyl-proline-(2-aminomethyl-5-chlorobenzyl)-amide bis(trifluoroacetate)
-
-
benzylsulfonyl-D-arginyl-proline-(4-amidinobenzyl)amide bis-(trifluoroacetate)
-
-
benzylsulfonyl-D-cyclohexylalanyl-proline-(2-aminomethyl-5-chlorobenzyl)amide
-
-
benzylsulfonyl-D-cyclohexylalanyl-proline-(4-amidinobenzyl)-amide
-
-
Bovine pancreatic trypsin inhibitor
-
BPTI
-
CJ-730
-
3-amidinophenylalanine-based inhibitor CJ-730, completely inhibits pro-HGF activation in PC3 cells
CVS-3983
-
a selective arginal-derived matriptase inhibitor
diisopropylfluorophosphate
-
complete inhibition at 5 mM
ethyl (3-[[(1S)-2-[4-(2-aminoethyl)piperidin-1-yl]-1-(3-carbamimidoylbenzyl)-2-oxoethyl]sulfamoyl]phenyl)carbamate
-
-
ethyl 4-(3,5-bis(4-carbamimidoylphenoxy)benzamido)piperidine-1-carboxylate
-
-
ethyl 4-(N-[[3-(beta-alanylamino)phenyl]sulfonyl]-3-carbamimidoyl-L-phenylalanyl)piperazine-1-carboxylate
-
-
GACTKSIPPICFPD
-
a mutant of sunflower trypsin inhibitor-17
GAVCPKILKKCRRDSDCPGACICRGNGYCGSGSD
-
a mutant of Momordica cochinchinensis trypsin inhibitor-II
GGACPKILKKCRRDSDCPGACICRGNGYCGSGSD
-
a mutant of Momordica cochinchinensis trypsin inhibitor-II
GGRCPKALKKCRRDSDCPGACICRGNGYCGSGSD
-
a mutant of Momordica cochinchinensis trypsin inhibitor-II
GGRCPKILKKCRRDSDCPGACICRGNGYCGSGSD
-
a mutant of Momordica cochinchinensis trypsin inhibitor-II
GGVCAKILKKCRRDSDCPGACICRGNGYCGSGSD
-
a mutant of Momordica cochinchinensis trypsin inhibitor-II
GGVCPAILKKCRRDSDCPGACICRGNGYCGSGSD
-
a mutant of Momordica cochinchinensis trypsin inhibitor-II
GGVCPKALKKCRRDSDCPGACICRGNGYCGSGSD
-
a mutant of Momordica cochinchinensis trypsin inhibitor-II
GGVCPKIAKKCRRDSDCPGACICRGNGYCGSGSD
-
a mutant of Momordica cochinchinensis trypsin inhibitor-II
GGVCPKILAKCRRDSDCPGACICRGNGYCGSGSD
-
a mutant of Momordica cochinchinensis trypsin inhibitor-II
GGVCPKILKACRRDSDCPGACICRGNGYCGSGSD
-
a mutant of Momordica cochinchinensis trypsin inhibitor-II
GGVCPKILKKCRRDSDCPGACICRGAGYCGSGSD
-
a mutant of Momordica cochinchinensis trypsin inhibitor-II
GGVCPKILKKCRRDSDCPGACICRGNGACGSGSD
-
a mutant of Momordica cochinchinensis trypsin inhibitor-II
GGVCPKILKKCRRDSDCPGACICRGNGYCASGSD
-
a mutant of Momordica cochinchinensis trypsin inhibitor-II
GGVCPKILKKCRRDSDCPGACICRGNGYCGAGSD
-
a mutant of Momordica cochinchinensis trypsin inhibitor-II
GGVCPKRLKKCRRDSDCPGACICRGNGYCGSGSD
-
a mutant of Momordica cochinchinensis trypsin inhibitor-II
GGVCPRILKKCRRDSDCPGACICRGNGYCGSGSD
-
a mutant of Momordica cochinchinensis trypsin inhibitor-II
GKCTKSIPPICFPD
-
a mutant of sunflower trypsin inhibitor-6
GRCAKSIPPICFPD
-
a mutant of sunflower trypsin inhibitor-16
GRCTASIPPICFPD
-
a mutant of sunflower trypsin inhibitor-15
GRCTKAIPPICFPD
-
a mutant of sunflower trypsin inhibitor-14
GRCTKSAPPICFPD
-
a mutant of sunflower trypsin inhibitor-13
GRCTKSAPPRCFPD
-
a mutant of sunflower trypsin inhibitor-1
GRCTKSIAPICFPD
-
a mutant of sunflower trypsin inhibitor-12
GRCTKSIPAICFPD
-
a mutant of sunflower trypsin inhibitor-11
GRCTKSIPPACFPD
-
a mutant of sunflower trypsin inhibitor-10
GRCTKSIPPDCFPD
-
a mutant of sunflower trypsin inhibitor-3
GRCTKSIPPGCFPD
-
a mutant of sunflower trypsin inhibitor-2
GRCTKSIPPICAPD
-
a mutant of sunflower trypsin inhibitor-9
GRCTKSIPPICFAD
-
a mutant of sunflower trypsin inhibitor-8
GRCTKSIPPICFPA
-
a mutant of sunflower trypsin inhibitor-7
GRCTKSIPPICFPD
-
-
-
GRCTKSIPPKCFPD
-
a mutant of sunflower trypsin inhibitor-0
GRCTKSIPPRCFPD
-
a mutant of sunflower trypsin inhibitor-1
GRCTKSRPPICFPD
-
a mutant of sunflower trypsin inhibitor-4
GRCTRSIPPICFPD
-
a mutant of sunflower trypsin inhibitor-5
hepatcyte growth factor activator inhibitor-1
-
in normal skin matriptase is complexed to hepatcyte growth factor activator inhibitor-1 wheras in squamous cell carcinoma the enzyme is present in an unassociated form
-
hepatocyte activation inhibitor 1
-
HAI-1, inhibition of matriptase
-
hepatocyte growth factor activator inhibitor
-
hepatocyte growth factor activator inhibitor 1
-
hepatocyte growth factor activator inhibitor I
-
-
-
hepatocyte growth factor activator inhibitor type 1
-
physiological inhibitor of matriptase. Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is required for the extracellular appearance of the protease in an expression system using a monkey kidney COS-1 cell line. In COS-1 cells co-expressing a variant form of HAI-1 without the responsible inhibition domain, matriptase does not appear in the conditioned medium
-
hepatocyte growth factor activator inhibitor type 2
-
HAI-2
-
hepatocyte growth factor activator inhibitor type I
-
hepatocyte growth factor activator inhibitor type-1
-
-
-
hepatocyte growth factor activator inhibitor-1
-
hepatocyte growth factor activator inhibitor-2
-
hexamidine
-
; and its structural analogs
KNAR
-
more selective for matriptase compared to matriptase-2
L-arginyl-L-glutaminyl-N-[(2S)-1-(1,3-benzothiazol-2-yl)-5-carbamimidamido-1-hydroxypentan-2-yl]-L-alaninamide
-
L-arginyl-N1-[(2S)-1-[[(2R)-1-(1,3-benzothiazol-2-yl)-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-L-glutamamide
-
L-arginyl-N1-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-L-glutamamide
L-arginyl-N1-[(2S)-1-[[(2S)-6-amino-1-(1,3-benzothiazol-2-yl)-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]-L-glutamamide
-
leupeptin
-
-
LWWR
-
2-fold selectivity for matriptase-2 against matriptase
methyl (2R)-1-(N-[[3-(beta-alanylamino)phenyl]sulfonyl]-3-carbamimidoyl-L-phenylalanyl)piperidine-2-carboxylate
-
-
methyl (2S)-1-(N-[[3-(beta-alanylamino)phenyl]sulfonyl]-3-carbamimidoyl-L-phenylalanyl)piperidine-2-carboxylate
-
-
methyl 4-[1-(N-[[3-(beta-alanylamino)phenyl]sulfonyl]-3-carbamimidoyl-L-phenylalanyl)piperidin-4-yl]butanoate
-
-
N-((1r,4r)-4-aminocyclohexyl)-3,5-bis((3-carbamimidoylbenzyl)oxy)benzamide
-
-
N-((1r,4r)-4-aminocyclohexyl)-3,5-bis((4-carbamimidoylbenzyl)oxy)benzamide
-
-
N-((1r,4r)-4-aminocyclohexyl)-3,5-bis(4-(aminomethyl)phenoxy)benzamide
-
-
N-((1r,4r)-4-aminocyclohexyl)-3-((3-carbamimidoylbenzyl)oxy)-5-(4-carbamimidoylphenoxy)benzamide
-
-
N-((1r,4r)-4-aminocyclohexyl)-3-((4-bromobenzyl)oxy)-5-(4-carbamimidoylphenoxy)benzamide
-
-
N-((1r,4r)-4-aminocyclohexyl)-3-((4-carbamimidoylbenzyl)oxy)-5-(4-carbamimidoylphenoxy)benzamide
-
-
N-((1r,4r)-4-aminocyclohexyl)-3-((6-aminopyridin-3-yl)oxy)-5-(4-carbamimidoylphenoxy)benzamide
-
-
N-((1r,4r)-4-aminocyclohexyl)-3-((6-bromopyridin-3-yl)methoxy)-5-(4-carbamimidoylphenoxy)benzamide
-
-
N-((1r,4r)-4-aminocyclohexyl)-3-(4-(3-aminopropanamido)phenoxy)-5-(4-carbamimidoylphenoxy)benzamide
-
-
N-((1r,4r)-4-aminocyclohexyl)-3-(4-(aminomethyl)phenoxy)-5-(4-carbamimidoylphenoxy)benzamide
-
-
N-((1r,4r)-4-aminocyclohexyl)-3-(4-aminophenoxy)-5-(4-carbamimidoylphenoxy)benzamide
-
-
N-((1r,4r)-4-aminocyclohexyl)-3-(4-carbamimidoylphenoxy)-5-((4-chlorobenzyl)oxy)benzamide
-
-
N-((1r,4r)-4-aminocyclohexyl)-3-(4-carbamimidoylphenoxy)-5-(4-carbamoylphenoxy)benzamide
-
-
N-(1-(3-aminopropyl)piperidin-4-yl)-3,5-bis(4-carbamimidoylphenoxy)benzamide
-
-
N-(2-aminoethyl)-1-(3-carbamimidoyl-N-[[2,4,6-tris(1-methylethyl)phenyl]sulfonyl]-L-phenylalanyl)piperidine-4-carboxamide
-
-
N-(3,5-bis(4-carbamimidoylphenoxy)phenyl)-1-(2-hydroxyethyl)piperidine-4-carboxamide
-
-
N-(3-[[(1R)-2-[4-(2-aminoethyl)piperidin-1-yl]-1-(3-carbamimidoylbenzyl)ethyl]sulfamoyl]phenyl)-beta-alaninamide
-
-
N-(3-[[(1S)-1-(3-carbamimidoylbenzyl)-2-(2-methylpiperidin-1-yl)-2-oxoethyl]sulfamoyl]phenyl)-beta-alaninamide
-
-
N-(3-[[(1S)-1-(3-carbamimidoylbenzyl)-2-(4-methylpiperidin-1-yl)-2-oxoethyl]sulfamoyl]phenyl)-beta-alaninamide
-
-
N-(3-[[(1S)-1-(3-carbamimidoylbenzyl)-2-oxo-2-piperazin-1-ylethyl]sulfamoyl]phenyl)-beta-alaninamide
-
-
N-(3-[[(1S)-1-(3-carbamimidoylbenzyl)-2-oxo-2-piperidin-1-ylethyl]sulfamoyl]phenyl)-beta-alaninamide
-
-
N-(3-[[(1S)-1-(3-carbamimidoylbenzyl)-2-[4-[4-(methylamino)-4-oxobutyl]piperidin-1-yl]-2-oxoethyl]sulfamoyl]phenyl)azetidine-3-carboxamide
-
-
N-(3-[[(1S)-1-[[4-(2-aminoethyl)piperidin-1-yl]carbonyl]-3-phenylpropyl]sulfamoyl]phenyl)-beta-alaninamide
-
-
N-(3-[[(1S)-1-[[4-(2-aminoethyl)piperidin-1-yl]carbonyl]-4-phenylbutyl]sulfamoyl]phenyl)-beta-alaninamide
-
-
N-(3-[[(1S)-2-(4-benzylpiperidin-1-yl)-1-(3-carbamimidoylbenzyl)-2-oxoethyl]sulfamoyl]phenyl)-beta-alaninamide
-
-
N-(3-[[(1S)-2-[4-(2-aminoethyl)piperidin-1-yl]-1-(3-carbamimidoylbenzyl)-2-oxoethyl]sulfamoyl]phenyl)-3-hydroxypropanamide
-
-
N-(3-[[(1S)-2-[4-(2-aminoethyl)piperidin-1-yl]-1-(3-carbamimidoylbenzyl)-2-oxoethyl]sulfamoyl]phenyl)-b-alaninamide
-
-
N-(3-[[(1S)-2-[4-(2-aminoethyl)piperidin-1-yl]-1-(3-carbamimidoylbenzyl)-2-oxoethyl]sulfamoyl]phenyl)-beta-alaninamide
-
-
N-(3-[[(1S)-2-[4-(2-aminoethyl)piperidin-1-yl]-1-(3-carbamimidoylbenzyl)-2-oxoethyl]sulfamoyl]phenyl)azetidine-3-carboxamide
-
-
N-(3-[[(1S)-2-[4-(2-aminoethyl)piperidin-1-yl]-1-(3-carbamimidoylbenzyl)-2-oxoethyl]sulfamoyl]phenyl)propanamide
-
-
N-(3-[[(1S)-2-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-1-(3-carbamimidoylbenzyl)-2-oxoethyl]sulfamoyl]phenyl)-beta-alaninamide
-
-
N-(3-[[(2S)-1-[4-(2-aminoethyl)piperidin-1-yl]-3-(3-carbamimidoylphenyl)-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
-
inhibitor completely prevents matriptase zymogen activation in human adenocarcinoma cell lines AsPC-1 and BxPC-3. Pro-urokinase-type plasminogen activator activation is completely abolished by matriptase inhibition. Matriptase inhibitors reduce the phosphorylation of the HGF receptor/cMet and the overall cellular invasiveness of the human pancreatic adenocarcinoma cell line AsPC-1
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-oxo-1-(piperazin-1-yl)propan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
-
inhibitor completely prevents matriptase zymogen activation in human adenocarcinoma cell lines AsPC-1 and BxPC-3. Pro-urokinase-type plasminogen activator activation is completely abolished by matriptase inhibition. Matriptase inhibitors reduce the phosphorylation of the HGF receptor/cMet and the overall cellular invasiveness of the human pancreatic adenocarcinoma cell line AsPC-1
N-(4-aminocyclohexyl)-3,5-bis(4-carbamimidoylphenoxy)benzamide
-
-
N-(4-aminocyclohexyl)-O-(3-carbamimidoylphenyl)-N2-(naphthalen-2-ylsulfonyl)-L-serinamide
-
-
N-(benzylsulfonyl)-3-cyclohexylalanyl-N-(4-carbamimidoylbenzyl)-L-prolinamide
-
; inhibitor modeling in the wild-type enzyme active site, overview
N-(benzylsulfonyl)-3-cyclohexylalanyl-N-[2-(aminomethyl)-5-chlorobenzyl]-L-prolinamide
-
;
N-[(1S)-2-[4-(2-aminoethyl)piperidin-1-yl]-1-[3-(aminomethyl)benzyl]-2-oxoethyl]-4'-methoxybiphenyl-3-sulfonamide
-
-
N-[3-([(1S)-1-(3-carbamimidoylbenzyl)-2-[4-(4-hydroxyphenyl)piperazin-1-yl]-2-oxoethyl]sulfamoyl)phenyl]-beta-alaninamide
-
-
N-[3-([(1S)-2-[4-(2-aminoethyl)piperidin-1-yl]-1-benzyl-2-oxoethyl]sulfamoyl)phenyl]-beta-alaninamide
-
-
N-[3-([(1S)-2-[4-(2-aminoethyl)piperidin-1-yl]-1-[3-(aminomethyl)benzyl]-2-oxoethyl]sulfamoyl)phenyl]-beta-alaninamide
-
-
N-[3-([(1S)-2-[4-(2-aminoethyl)piperidin-1-yl]-1-[4-(aminomethyl)benzyl]-2-oxoethyl]sulfamoyl)phenyl]-beta-alaninamide
-
-
N-[3-([1-[4-(2-aminoethyl)piperidin-1-yl]-3-(3-carbamimidoylphenyl)-1-oxopropan-2-yl]sulfamoyl)phenyl]-b-alaninamide
-
-
N1-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-L-glutamamide
-
N2-(benzylsulfonyl)arginyl-N-(4-carbamimidoylbenzyl)-L-prolinamide
-
;
N2-(benzylsulfonyl)arginyl-N-[2-(aminomethyl)-5-chlorobenzyl]-L-prolinamide
-
;
O-(3-carbamimidoylphenyl)-N-(4-methylcyclohexyl)-N2-(naphthalen-2-ylsulfonyl)-L-serinamide
-
-
plasminogen activator inhibitor I
-
-
-
plasminogen activator inhibitor-1
-
formation of a stable inhibitor complex
Protein C inhibitor
-
formation of a stable inhibitor complex
-
R1K'4-eglin
-
different eglin c variants with differing inhibitory potential versus matriptase, construction, expression and purification of eglin c variants and screening for inhibitory potency, overview, R1K'4-eglin has the wild-type Pro45 at P1 position and Tyr49 at P4' position residues replaced with Arg and Lys, respectively, leads to the production of a selective, high affinity and proteolytically stable inhibitor of matriptase, molecular modeling of enzyme-inhibitor complex, overview
-
R1K4-eglin
-
wild type eglin c with Pro45 at P1 position and Tyr49 residues at P4 position replaced with Arg and Lys respectively, most potent, selective, high affinity and proteolytically stable inhibitor
R4R1-eglin
-
with substituted P42 and L45 for arginine residues, variants containing an Arg or Lys at position 49 instead of the original Tyr residue show enhanced inhibition
RLSR
-
-
RNPR
-
more selective for matriptase compared to matriptase-2
scFv antibody E2
-
competitive mechanism of inhibition of the scFv antibody enzyme inhibitors, which competes with substrate binding in the S1 site, the antibody binds to a number of residues flanking the active site, forming a unique three-dimensional binding epitope
-
scFv antibody S4
-
competitive mechanism of inhibition of the scFv antibody enzyme inhibitors, which competes with substrate binding in the S1 site, the antibody binds to a number of residues flanking the active site, forming a unique three-dimensional binding epitope
-
SFTI1
-
serine protease inhibitor can only inhibit Epi/MTP and cathepsin G. Mammary epithelial growth and morphogenesis in the presence of the latent form hepatocyte growth factor (pro-HGF) is blocked by addition of SFTI1 an inhibitor of the Epi/MTP protease activity
single chain variable fragment of antibodies
-
different variants
-
sulfated 3-amidinophenylalanine derivatives
-
deiverse variants, overview
-
sulfonylated 3-amidino-phenylalanine inhibitors
-
-
-
sunflower trypsin inhibitor
-
SFTI-1
-
sunflower trypsin inhibitor-1
sunflower trypsin inhibitor-2
-
SFTI-2
sunflower trypsin inhibitor-3
-
SFTI-3
WCYR
-
more selective for matriptase compared to matriptase-2
WRER
-
more selective for matriptase compared to matriptase-2
YKAR
-
-
YYVR
-
13times more selective for matriptase-2 than matriptase
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
4,4'-diisothiocyanatostilbene-2,2' disulfonic acid
-
as an early response to acidosis, matriptase activation can also be induced by perturbation of intracellular pH homeostasis using substances inhibiting Na+/H+ exchangers or other acid-base ion channels
5-(N-ethyl-N-isopropyl)-amiloride
-
as an early response to acidosis, matriptase activation can also be induced by perturbation of intracellular pH homeostasis using substances inhibiting Na+/H+ exchangers or other acid-base ion channels
5-(N-methyl-N-isobutyl)-amiloride
-
as an early response to acidosis, matriptase activation can also be induced by perturbation of intracellular pH homeostasis using substances inhibiting Na+/H+ exchangers or other acid-base ion channels
C2 ceramide 1-phosphate
-
weaker activator than sphingosine 1-phosphate, activation at 0.000237 mM
C8 ceramide 1-phosphate
-
weaker activator than sphingosine 1-phosphate, activation at 0.001 mM
dihydrosphingosine 1-phosphate
-
weaker activator than sphingosine 1-phosphate
enterokinase
-
-
-
Epidermal growth factor
-
stimulates the release of matripase/hepatocyte growth factor activator inhibitor-1 complexes
H+
-
exposure of epithelial and carcinoma cells to a mildly acidic extracellular milieu pH 6.0 results in robust matriptase activation
hepatocyte growth factor activator inhibitor
-
HAI-1, zymogen activator of matriptase
-
hepatocyte growth factor activator inhibitor-1
-
-
-
lysophosphatidic acid
-
weaker activator than sphingosine 1-phosphate
N-acetylglucosaminyltransferase V
-
the transient overexpression of N-acetylglucosaminyltransferase V, MGAT5, significantly enhances the activity of matriptase
-
prostasin
-
prostasin stimulates the conversion of the cell-associated 70-kDa matriptase zymogen to the two-chain active form. Prostasin induces matriptase zymogen activation in intestinal epithelial cells to regulate closure of the paracellular pathway. But active recombinant matriptase, however, does not require the expression of endogenous prostasin for barrier-forming activity
-
Serum
-
from human, horse, mouse, rat, rabbit, duck, chicken, goat, calf, turtle and foetal bovine serum, leads to increase of the level of the active two-chain form
-
sphingosine 1-phosphate
sphingosine phosphocholine
-
weaker activator than sphingosine 1-phosphate
Triton X-100
-
-
Trypsin
-
activates membrane-bound, latent matripase on the cell surface
-
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
35.5
ABZ-Ile-Arg-Ala-Arg-Ser-Ala-Ala-Tyr(3-NO2)-NH2
-
pH and temperature not specified in the publication
8.35
ABZ-Ile-Arg-Ala-Arg-Ser-Ala-Gly-Tyr(3-NO2)-NH2
-
pH and temperature not specified in the publication
24.5
ABZ-Ile-Arg-Ala-Arg-Ser-Ala-Ser-Tyr(3-NO2)-NH2
-
pH and temperature not specified in the publication
0.1 - 0.111
alphaEbeta7
-
0.024 - 1
Boc-Gln-Ala-Arg-4-nitroanilide
0.159 - 0.381
butyloxycarbonyl-L-Gln-L-Ala-L-Arg-4-nitroanilide
0.03 - 0.046
filaggrin
-
0.104 - 0.126
matriptase
-
0.17 - 0.19
methylsulfonyl-D-cyclohexyltyrosyl-glycyl-arginine-p-nitroanilide
0.164 - 0.228
methylsulfonyl-D-cyclohexyltyrosylglycyl-arginine-p-nitroanilide
0.0699
N-succinyl-Ala-Phe-Lys-7-amido-4-methylcoumarin
-
pH 8.5
0.00489 - 0.0335
N-tert-butoxycarbonyl-gamma-benzyl-Gln-Ala-Arg-7-amido-4-methylcoumarin
0.00381
N-tert-butoxycarbonyl-gamma-benzyl-Glu-Ala-Arg-7-amido-4-methylcoumarin
-
pH 8.5
0.0475
N-tert-butoxycarbonyl-gamma-benzyl-Glu-Gly-Arg-7-amido-4-methylcoumarin
-
pH 8.5
0.0136
N-tert-butoxycarbonyl-gamma-benzyl-Leu-Gly-Arg-7-amido-4-methylcoumarin
-
pH 8.5
0.0017
pro-urokinase plasminogen activator
-
-
-
0.142 - 0.197
protease-activated receptor-2
-
0.159
RAARVVGG
-
-
0.088
RLARVVGG
-
-
0.018 - 0.128
RQARAVGG
0.065
RQARQVGG
-
-
0.104 - 0.126
RQARVVGG
0.869
RQARYVGG
-
-
0.124
RQLRVVGG
-
-
0.05
RQRRVVGG
-
-
0.05
RQYRVVGG
-
-
0.0033 - 0.012
RRARVVGG
0.137
RYARVVGG
-
-
0.00352 - 0.00599
single-chain urokinase-type plasminogen activator
-
240
Suc-Ala-Ala-Pro-Arg-p-nitroanilide
-
-
534
Suc-Ala-Ala-Pro-Lys-p-nitroanilide
-
-
0.582 - 0.59
t-butyloxycarbonyl-L-Gln-L-Ala-L-Arg-4-methyl-coumaryl-7-amide
0.052 - 0.07
trask
-
additional information
additional information
-